Date: 2012-05-15
Type of information: Fundraising
Company: Gamida Cells (Israel)
Investors:
Amount: $10 Million
Funding type: financing round
Planned used: The financing will be used to support the global commercialization of the company’s lead cell therapy product, StemEx, in development as an alternative therapeutic treatment for patients with blood cancers, such as leukemia and lymphoma, who can be cured by bone marrow transplantation but do not have a matched bone marrow donor. The financing will also support the continued development of the company’s pipeline of products, primarily the NiCord® clinical trial for sickle cell disease and thalassemia.
Others: Gamida Cell has closed an internal E financing round of $10 million. All major shareholders participated. The company is currently seeking a strategic partner to join in the global commercialization of its cell therapy product StemEx®. The international, multi-center, pivotal registration, Phase III clinical trial of StemEx completed enrollment in February 2012. Clinical outcome is expected in Q4/2012. The market launch of StemEx is planned for 2013. StemEx is likely to be the first allogeneic stem cell product in the market. The product is being developed by the Gamida Cell-TEVA joint venture.
Therapeutic area: Cancer - Oncology
